Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) as a Single Agent and in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Next Previous
X
Search
Trial Profile

An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) as a Single Agent and in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aplitabart (Primary) ; Birinapant (Primary) ; Azacitidine; Bevacizumab; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Venetoclax
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Haematological malignancies; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors IGM Biosciences

    • Most Recent Events

    • 14 Aug 2024 According to an IGM Biosciences media release, the company has completed enrollment in its randomized clinical trial of 3 mg/kg of aplitabart plus FOLFIRI and bevacizumab in second-line metastatic colorectal cancer.
    • 14 Aug 2024 Status changed from recruiting to active, no longer recruiting, according to an IGM Biosciences media release.
    • 08 May 2024 According to an IGM Biosciences media release, company has also met its target of enrolling 20 patients in its single arm clinical study of 10 mg/kg of aplitabart in combination with FOLFIRI and bevacizumab in the treatment of later line colorectal cancer patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top